Hot update initiated MacroGenics, Inc. (MGNX) surge in the Post-market session

NXTP Stock
NXTP Stock

MacroGenics, Inc. (NASDAQ: MGNX), shares zipped 13.27% in the post-market to reached $28. A biopharmaceutical corporation devoted to the production and promotion of novel cancer medication monoclonal antibody-based therapeutics has confirmed that the U.S. MARGENZA, in combination with chemotherapy, has been regulated by the FDA for the treatment of adult patients with metastatic HER2-positive breast cancer who have undergone two or more previous anti-HER2 regimens, plus at least one for metastatic disease.

MARGENZA is being further developed by MacroGenics, with funding from Zai Lab in Greater China, for the treatment of advanced gastric cancer. The acceptance in the U.S. for breast cancer was focused on the safety and effectiveness findings of the Phase 3 SOPHIA pivotal trial.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


MARGENZA’s approval was based on the results of SOPHIA, a randomized Phase 3 clinical trial. This study included 536 patients and found a statistically significant 24% reduction in the risk of progression or death with MARGENZA plus chemotherapy compared with trastuzumab plus chemotherapy (P=0.033; median PFS 5.8 vs 4.9 months). The objective response rate for MARGENZA plus chemotherapy was 22% and for trastuzumab plus chemotherapy was 16%. The final Overall Survival (OS) analysis is expected in the second half of 2021.

Read More


Please enter your comment!
Please enter your name here